Gossamer Bio (GOSS) Non-Current Debt (2019 - 2023)
Gossamer Bio (GOSS) posted quarterly Non-Current Debt of $814000.0 for Q4 2023, down 93.21% year-over-year from $12.0 million in Q4 2022, and down 77.6% quarter-over-quarter from $3.6 million in Q3 2023.
Gossamer Bio (GOSS) Non-Current Debt (2019 - 2023) Analysis & Trends
Gossamer Bio's Non-Current Debt history runs 5 years deep, the most recent figure standing at $814000.0 for Q4 2023.
- In Q4 2023, Non-Current Debt fell 93.21% year-over-year to $814000.0; the TTM figure through Dec 2023 stood at $814000.0 (down 93.21% YoY), while the FY2023 annual figure was $814000.0, down 93.21% from the prior year.
- Non-Current Debt for Q4 2023 stood at $814000.0, down from $3.6 million in the prior quarter.
- The five-year high for Non-Current Debt was $29.2 million in Q1 2022, with the low at $814000.0 in Q4 2023.
- The 5-year median for Non-Current Debt is $28.5 million (2019), against an average of $21.5 million.
- The sharpest annual moves came in 2020 and 2023: Non-Current Debt grew 1.26% in 2020, then sank 93.21% in 2023.
- Gossamer Bio's Non-Current Debt stood at $28.5 million in 2019, then rose by 1.0% to $28.7 million in 2020, then grew by 1.17% to $29.1 million in 2021, then plunged by 58.77% to $12.0 million in 2022, then tumbled by 93.21% to $814000.0 in 2023.
- Business Quant data shows GOSS's Non-Current Debt at $814000.0 in Q4 2023, $3.6 million in Q3 2023, and $6.4 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 814,000.00 |
| Sep 30, 2023 | 3.63 Mn |
| Jun 30, 2023 | 6.44 Mn |
| Mar 31, 2023 | 9.22 Mn |
| Dec 31, 2022 | 11.99 Mn |
| Sep 30, 2022 | 14.83 Mn |
| Jun 30, 2022 | 17.65 Mn |
| Mar 31, 2022 | 29.17 Mn |
| Dec 31, 2021 | 29.08 Mn |
| Sep 30, 2021 | 28.99 Mn |
| Jun 30, 2021 | 28.91 Mn |
| Mar 31, 2021 | 28.82 Mn |
| Dec 31, 2020 | 28.74 Mn |
| Sep 30, 2020 | 28.67 Mn |
| Jun 30, 2020 | 28.64 Mn |
| Mar 31, 2020 | 28.55 Mn |
| Dec 31, 2019 | 28.46 Mn |
| Sep 30, 2019 | 28.37 Mn |
| Jun 30, 2019 | 28.28 Mn |